Sangamo Therapeutics, Inc. Stock price

Equities

SGMO

US8006771062

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.6702 USD +7.28% Intraday chart for Sangamo Therapeutics, Inc. -17.88% +23.36%
Sales 2024 * 36.94M Sales 2025 * 64.14M Capitalization 136M
Net income 2024 * -109M Net income 2025 * -82M EV / Sales 2024 * 4.8 x
Net Debt 2024 * 40.79M Net Debt 2025 * 129M EV / Sales 2025 * 4.14 x
P/E ratio 2024 *
-1.34 x
P/E ratio 2025 *
-2.18 x
Employees 405
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.55%
More Fundamentals * Assessed data
Dynamic Chart
Sangamo Therapeutics Prices $24 Million Registered Direct Offering MT
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says MT
Transcript : Sangamo Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023 CI
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sangamo Therapeutics Says Early Phase 1/2 Data Shows 'Durable' Safety, Efficacy of Fabry Disease Drug Candidate MT
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920 CI
Vaxcyte Names Chief People Officer MT
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from NASDAQ Biotechnology Index CI
Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial CI
North American Morning Briefing : Stock Futures -2- DJ
Truist Securities Downgrades Sangamo Therapeutics to Hold From Buy MT
North American Morning Briefing : Higher Bond -2- DJ
More news
1 day+7.28%
1 week-17.88%
Current month-42.22%
1 month-40.69%
3 months+24.80%
6 months+11.83%
Current year+23.36%
More quotes
1 week
0.59
Extreme 0.591
0.93
1 month
0.59
Extreme 0.591
1.19
Current year
0.39
Extreme 0.39
1.48
1 year
0.29
Extreme 0.2911
1.82
3 years
0.29
Extreme 0.2911
12.85
5 years
0.29
Extreme 0.2911
19.43
10 years
0.29
Extreme 0.2911
27.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 16-05-31
Director of Finance/CFO 46 19-02-28
Chief Tech/Sci/R&D Officer - 20-04-30
Members of the board TitleAgeSince
Director/Board Member 61 22-12-14
Director/Board Member 58 19-11-21
Chairman 68 14-06-18
More insiders
Date Price Change Volume
24-03-28 0.6702 +7.28% 1,252,490
24-03-27 0.6247 +3.53% 2,650,625
24-03-26 0.6034 -5.97% 2,282,595
24-03-25 0.6417 -8.72% 2,855,904
24-03-22 0.703 -27.55% 6,598,653

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
0.6702 USD
Average target price
3.5 USD
Spread / Average Target
+422.23%
Consensus
  1. Stock
  2. Equities
  3. Stock Sangamo Therapeutics, Inc. - Nasdaq